ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates levels of hsCRP, a clinical biomarker of inflammatio...

Full description

Bibliographic Details
Main Authors: Sergey Filippov, Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Jeffrey C. Hanselman, Clay T. Cramer, Rai Ajit K. Srivastava, Timothy R. Hurley, Cheryl D. Bradshaw, Mark A. Spahr, Roger S. Newton
Format: Article
Language:English
Published: Elsevier 2013-08-01
Series:Journal of Lipid Research
Subjects:
AMP-activated protein kinase
mitogen-activated protein kinases
liver kinase B1
macrophages/monocytes
cytokines
adipose tissue
Online Access:http://www.sciencedirect.com/science/article/pii/S002222752037526X

Internet

http://www.sciencedirect.com/science/article/pii/S002222752037526X

Similar Items